team work

2 Houston blockchain companies connect on ESG initiative

These two innovators have linked up for a new ESG offering. Photos courtesy

Two Houston-based startups specializing in blockchain technology have announced a collaborative within the Environmental, Social and Governance, or ESG, space.

Data Gumbo and Topl have partnered up to offer companies a private-public blockchain solution for ESG reporting. The collaborative solution, according to a news release, allows for public-facing, accurate, and immutable ESG progress reports that are accessible to outside audiences and stakeholders, including public analysts, investors, governments, and more.

"As companies today face mounting pressure to report timely and accurate ESG data, including performance and progress, they need the right tools to collect, standardize and automate reporting while preserving security for sensitive data," says Andrew Bruce, CEO and founder of Data Gumbo, in the release. "For the first time, this partnership offers companies total control of their accurate ESG data, allowing them to publish and report metrics in whatever manner best suits them satisfying investors', regulator agencies' and other stakeholders' desires."

The tool will gather business operation and transaction data and compare it to defined standards. This enables the complete review and certification of ESG metrics by auditors using GumboNet ESG. Once the environmental impact is determined, the company can easily share data recorded on Topl's public-facing blockchain.

"Companies can now comprehensively collect ESG data and report to private entities and public audiences," says Kim Raath, founder and CEO of Topl. "This partnership combines the power of our two complementary solutions to support a new level of transparency for companies that desire to showcase their fully verifiable progress on crucial ESG metrics."

Both companies have been players within the ESG space. Data Gumbo launched GumboNet ESG, a sustainability measurement solution that can pull together a company's operational data to ESG standards reporting, in March. Topl's blockchain-as-a-service offering rolled out just a few weeks later.

Trending News

Building Houston

 
 

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Trending News